cis-platemum

PreclinicalSmall molecule

JJun Liu

cis-platemum is one of 52 small molecule programs targeting Neoadjuvant Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoadjuvant TherapyUnknown status

Neoadjuvant TherapyPreclinical

Unknown status

Competition

Competitive Landscape

60 competitors in Neoadjuvant Therapy

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 3

2 2

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

5 3

Tuoyi

CCoherus Oncology, Inc.

Phase 3

2 4

Keytruda

Merck & Co.

Phase 2

5 5

Avastin

Roche

Phase 2

4 6

Beyfortus

BeiGene

Phase 2

4 7

Abraxane

Bristol-Myers Squibb

Phase 2

3 8

Eloxatin

Teva

Phase 2

2 9

Ellence

Pfizer

Phase 2

2 10

Tagrisso

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neoadjuvant Therapy1 trial

A Single-arm Exploratory Study of Neoadjuvant Therapy

Unknown status·JJun Liu·N/A·NCT05527808·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cis-platemum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cis-platemum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cis-platemum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jun Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: JJun Liu

cis-platemum

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neoadjuvant Therapy1 trial

References

Drug Info

Quick Facts

Related News